TOP2/YNL088W Literature Guide Help

Other names published for TOP2: TOR3, TRF3, DNA topoisomerase 2, YNL088W

TOP2 - Other Features (20)

ReferenceOther Genes Addressed
Warkocki Z, et al.  (2009) Reconstitution of both steps of Saccharomyces cerevisiae splicing with purified spliceosomal components. Nat Struct Mol Biol 16(12):1237-43
Byl JA, et al.  (2001) DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry 40(3):712-8
Morris SK, et al.  (2000) Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193. J Biol Chem 275(4):2613-8
Morris SK and Lindsley JE  (1999) Yeast topoisomerase II is inhibited by etoposide after hydrolyzing the first ATP and before releasing the second ADP. J Biol Chem 274(43):30690-6
van Hille B, et al.  (1999) Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. Br J Cancer 81(5):800-7
Reid RJ, et al.  (1998) Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Biochim Biophys Acta 1400(1-3):289-300
Sabourin M, et al.  (1998) A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP. J Biol Chem 273(44):29086-92
Nitiss JL and Wang JC  (1996) Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 50(5):1095-102
Skladanowski A, et al.  (1996) Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 49(5):772-80
Elsea SH, et al.  (1995) A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. J Biol Chem 270(4):1913-20
Froelich-Ammon SJ and Osheroff N  (1995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 270(37):21429-32
Vassetzky YS, et al.  (1995) DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays 17(9):767-74
Chen AY and Liu LF  (1994) Mechanisms of resistance to topoisomerase inhibitors. Cancer Treat Res 73():263-81
Liu YX, et al.  (1994) Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res 54(11):2943-51
Nitiss JL, et al.  (1994) Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine. Mol Pharmacol 46(4):773-7
Roca J, et al.  (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A 91(5):1781-5
Shen LL and Fostel JM  (1994) DNA topoisomerase inhibitors as antifungal agents. Adv Pharmacol 29B():227-44
Bojanowski K, et al.  (1992) Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci U S A 89(7):3025-9
Pocklington MJ, et al.  (1990) The effect of novobiocin on yeast topoisomerase type II. Mol Gen Genet 220(2):256-60
Goto T and Wang JC  (1982) Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings. J Biol Chem 257(10):5866-72